Erratum: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors (Clin Cancer Res (2022) 28 (1302–1312) DOI: 10.1158/1078-0432.ccr-21-3597)

George D. Demetri, Filippo De Braud, Alexander Drilon, Salvatore Siena, Manish R. Patel, Byoung Chul Cho, Stephen V. Liu, Myung Ju Ahn, Chao Hua Chiu, Jessica J. Lin, Koichi Goto, Jeeyun Lee, Lyudmila Bazhenova, Thomas John, Marwan Fakih, Sant P. Chawla, Rafal Dziadziuszko, Takashi Seto, Sebastian Heinzmann, Bethany PitcherDavid Chen, Timothy R. Wilson, Christian Rolfo

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the earlier version of this article as it was published online on February 10, 2022 (1) and in the printed article, the disclosures of Salvatore Siena and Jeeyun Lee were missing. The HTML and PDF versions of this article were corrected in the online release of the April 1, 2022 issue (2). The publisher regrets the error.

Original languageEnglish (US)
Pages (from-to)2196
Number of pages1
JournalClinical Cancer Research
Volume28
Issue number10
DOIs
StatePublished - May 15 2022

Bibliographical note

Publisher Copyright:
©2022 American Association for Cancer Research

PubMed: MeSH publication types

  • Published Erratum

Fingerprint

Dive into the research topics of 'Erratum: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors (Clin Cancer Res (2022) 28 (1302–1312) DOI: 10.1158/1078-0432.ccr-21-3597)'. Together they form a unique fingerprint.

Cite this